An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Sponsors Sarepta Therapeutics
- 18 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 19 Sep 2016 According to CureDuchenne Ventures media release, eteplirsen received accelerated approval from the Food and Drug Administration to treat Duchenne muscular dystrophy.